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Novelty and Impact Statements: The current debate about over-treatment of non-invasive and 
indolent breast carcinomas calls for diagnostic measures of malignant potential. Robust markers of 
progression may help reduce the overtreatment. MicroRNAs are stable molecules with impact on 
gene-expression. Breast cancer is a heterogeneous disease and subtype-specific markers of 
progression and invasiveness are needed in order to identify relevant alterations. In this study, a 
subtype-specific microRNA signature predicting malignant potential is proposed.  
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Abstract 
Robust markers of invasiveness may help reduce the overtreatment of in situ carcinomas. . Breast 
cancer is a heterogeneous disease and biological mechanisms for carcinogenesis vary between 
subtypes. Stratification by subtype is therefore necessary in order to identify relevant and robust 
signatures of invasive disease. We have identified miRNA alterations during breast cancer 
progression in two separate datasets and used stratification and external validation to strengthen 
the findings.  
We analysed two separate datasets (METABRIC and AHUS) consisting of a total of 186 normal breast 
tissue samples, 18 ductal carcinoma in situ (DCIS) and 1338 invasive breast carcinomas. Validation in 
a separate dataset and stratification by molecular subtypes based on immunohistochemistry, PAM50 
and integrated cluster classifications were performed.  
We propose subtype-specific miRNA signatures of invasive carcinoma and a validated signature of 
DCIS. miRNAs included in the invasive signatures include down-regulation of miR-139-5p in 
aggressive subtypes and up-regulation of miR-29c-5p expression in the luminal subtypes. No miRNAs 
were differentially expressed in the transition from DCIS to invasive carcinomas on the whole, 
indicating the need for subtype stratification. A total of 27 miRNAs were included in our proposed 
DCIS-signature. Significant alterations of expression included up-regulation of miR-21-5p and the 
miR-200-family and down-regulation of let-7 family members in DCIS samples. The signatures 
proposed here can form the basis for studies exploring DCIS samples with increased invasive 
potential and serum biomarkers for in situ and invasive breast cancer.  
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Introduction 
Breast cancer is a life-threatening disease where early diagnosis reduces the risk of systemic 
involvement and thus improves prognosis. Identification of molecular alterations during the 
carcinogenic process from normal tissue to ductal carcinoma in situ (DCIS) and invasive cancer is 
important in order to understand the underlying biological processes, to identify biological tumour 
markers for early detection and to discover possible preventive and predictive measures. We 
propose microRNA (miRNA) expression signatures characteristic of the transition from normal breast 
tissue to DCIS and of DCIS to invasive cancer based on breast tissue whole genome miRNA expression 
data collected from two separate studies, METABRIC and AHUS.  
The molecular mechanisms responsible for progression are poorly understood, although alterations 
between the normal and benign breast tissue as well as of malignant breast tumours have been 
published previously [1,2]. Due to power insufficiency, these studies did not investigate progression 
in a subtype-specific manner, a gap we are proposing to fill with the present dataset and analysis. 
Women with high mammographic density or benign breast lesions are at higher risk of developing 
malignant breast disease, but having difficult to interpret mammograms may mask the early stages 
of malignancy [3]. Therefore, having molecular markers, particularly if available in the circulation, 
may aid the diagnostic process.  
DCIS is a disease that is not in itself life-threatening. Most lesions will not progress to invasive disease 
[4], but since we lack knowledge of which lesions will progress, all patients are treated radically to 
prevent progression. Biological markers of progression may enable reduction of the over-treatment 
of this group of patients. Since most patients with DCIS are treated with surgery and/or radiotherapy 
and very few women choose watchful surveillance there is a lack of information of which DCIS lesions 
will progress and therefore surrogate end-points must be used. One commonly employed strategy is 
to identify characteristics of the women with DCIS that will relapse or be diagnosed with invasive 
breast cancer later. Such a cohort captures women who are insufficiently treated for DCIS, but will 
mostly consist of women with second primary malignant breast disease and may hence lead to 
identification of factors associated with increased risk rather than progression [5]. An alternative 
strategy is to look for characteristics of invasive carcinoma in DCIS lesions [1]. Signatures of miRNAs 
differentially expressed between invasive carcinomas and DCIS samples, as developed in this study, 
may be used to create single sample predictors that look for invasiveness-like expression pattern in 
DCIS samples, first in a retrospective and later in a diagnostic setting.   
The driving mechanisms of breast carcinogenesis and the resulting intra-tumour heterogeneity have 
been explained by clonal evolution [6]. This theory suggests that cancer arises in a normal cell 
through the accumulation of carcinogenic genetic aberrations in a multistep process. Later, cancer 
cells will acquire new genetic aberrations giving rise to new clones. This multistep process transforms 
the clone from normal cells to hyperplastic/benign cells and further to carcinoma cells that are 
confined by the basement membrane (DCIS) and, finally to carcinoma cells that have the capability of 
invading surrounding tissues and metastasizing. According to this model, it should be possible to 
detect lesions at pre-malignant stages to prevent invasive disease.  
miRNAs are a class of small RNA molecules that regulate their target mRNAs by translational 
repression, or by aiding increased rates of mRNA degradation. miRNAs are associated with several 
cellular processes such as proliferation, apoptosis, stress response and carcinogenesis [7]. Enerly and 
colleagues identified miRNAs differentially expressed between different molecular subtypes of breast 
cancer and miRNAs related to molecular characteristics of the tumour (such as TP53 mutations and 
estrogen receptor (ER) status) [8]. Aure et al identified miRNAs whose expression was consistently 
deregulated by DNA copy number alterations and methylation [9] and identified clusters of miRNAs 
that are collectively associated with the expression of key proteins (growth factors, their receptors 
and serine-tyrosine kinases)  in breast cancer [10]. Dvinge and colleagues published an in-depth 
analysis of the miRNA profiles in the METABRIC dataset, which is also included in our analyses [11]. 
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They focused on prognostic signatures, as well as an exploration of functional associations of miRNA 
networks, but they did not report progression signatures.   
Several different approaches are used to subtype breast cancer. In the clinic, immunohistochemistry 
and fluorescent imaging classify tumours according to expression of ER and progesterone receptor 
(PGR), human epidermal growth factor 2 (HER2) receptor status and partly by the proliferation 
marker Ki67. Based on gene expression microarray status, five intrinsic subtypes were identified [12]. 
These subtypes have proven to be robust and clinically relevant. Refinement of the gene lists used 
for subtyping has resulted in the PAM50 classification [13]. Combining gene expression with copy 
number alterations, integrated clusters (IC) were identified carrying additional clinical and prognostic 
relevance [14].  
Here, we report miRNA profiles characterizing the different transitions that occur during breast 
carcinogenesis, from normal breast tissue to DCIS and from DCIS to subtype-specific invasive 
carcinomas based on material from two different studies.  The overlap between the DCIS-signature 
described here and that previously published by Volinia et al [1] is reported as validated miRNA 
signature of progression.  
Material and methods 
miRNA gene expression datasets have been collected from two different studies. Data from a total of 
1542 breast tissue samples were included in this study: 186 normal breast tissue samples, 18 DCIS 
lesions and 1338 invasive carcinomas (Table Additional file 1A). The cohorts are described below.  
AHUS (Akershus University Hospital) 
The Akershus University Hospital has sequentially collected breast tissue specimens from breast 
cancer patients and from women undergoing surgery for breast reduction. The patients were 
included from 2003 to 2009. miRNA expression profiling was obtained for 55 invasive carcinomas, 8 
DCIS samples and 70 normal breast tissue samples (including 29 tumour-adjacent normal tissue 
samples and 41 breast reduction samples). The samples were hybridized on Agilent 8x15K arrays 
(Agilent Technologies, Santa Clara, CA, USA), catalogue number 4470B (v2) and 4470C (v3), and the 
features were extracted using Agilent Feature Extraction. Parts of the dataset has been published 
previously [2].The complete dataset is available in the ArrayExpress database 
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-3759. Ethical approval was obtained 
by the Regional ethical committee South-East by reference numbers 429-04148 and 2014/895.  
METABRIC (University of Cambridge) 
The University of Cambridge has provided a dataset consisting of miRNA expression from 1283 breast 
cancer patients with 116 matched tumour-adjacent normal breast tissues as part of the METABRIC 
dataset previously published [11] and available in the European Genome-phenome Archive 
(EGAS00000000122). From the 1302 tumour samples, those described as phyllodes (n=5), benign 
(n=3) or null (n=1) were removed. 10 additional DCIS samples were included. The samples were 
hybridized on custom Agilent-miRNA-60K arrays (Agilent Technologies, Santa Clara, CA, USA), as 
previously described [11]. Ethical approval for the METABRIC study protocol was obtained from the 
ethics committees in Cambridge and Vancouver. 
All patients in both studies have signed informed consent. Sample annotation for both cohorts is 
available in Additional file 21, including subtype classification. .  
Validation cohort 
Volinia and colleagues [1] published lists of differentially expressed genes based on a dataset 
published by Farazi and colleagues [15] consisting of sequenced miRNA profiles from 11 normal 
breast tissues, 17 DCIS samples and 151 invasive breast carcinomas, in addition to 6 cell lines. Of 
these, Volinia and colleagues used the profiles of 6 normal breast tissues, 8 DCIS samples and 80 
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invasive breast carcinomas to create transition signatures from normal to DCIS and from DCIS to 
invasive breast cancer, containing 66 and 9 miRNAs respectively [1].  
Data processing 
The METABRIC dataset was provided in a processed format, as described in Dvinge et al. The AHUS 
samples were provided as Agilent Feature Extraction result files. These were read in using the the R 
library AgiMicroRna [16] and then normalized using rma [17] without background subtraction [18]. 
MicroRNAs detected in fewer than 75% of the samples in at least one clinical category were omitted. 
To account for discrepancies in miRNA nomenclature due to different miRBase releases, the feature 
names were converted to MIMAT ids using a mapping file downloaded from miRBase [19].  Only 
miRNA features common to both datasets were analysed.  
Statistical analyses 
A clear batch effect was observed between the two data sets. To mitigate this, two analytical 
approaches were used, both using the limma  package to detect differentially expressed genes 
between the clinical groups [20]. In the "meta" approach, the data sets were analyzed individually as 
well as combined by using the p-values in a meta-analysis. In the "merged" approach, the two data 
sets were combined and then analyzed with the data set source included as a blocking factor. A 
miRNA was reported as differentially expressed if its false discovery rate (FDR) was <0.05 in both 
analyses [21]. Information about the genomic location of the miRNAs was collected from the UCSC 
genome browser, hg19 assembly [22].  
Differential expression (limma [20]) was used in an attempt to identify miRNAs accompanying the 
progression from DCIS to carcinoma. Due to the relatively small number of DCIS samples, they were 
included in the contrasts as a single group. Tumours were classified in alternative ways, by using 
routine immunohistochemical parameters (status of ER, PGR and HER2 receptor), gene expression 
(PAM50 [13]) or integrative genomic analysis [14]. Since data on copy number alterations was only 
available for the METABRIC samples, stratification by the IC-subgroups was only performed on this 
dataset. PAM50 subtype is given for DCIS samples where mRNA data was available (Additional file 1A 
and 2). Hierarchical clustering with Euclidean distance and complete linkage was performed by the 
function heatmap.2 within the R-package gplots.   
miRNAs curation 
miRNA probes were classified according to their likelihood to represent bona fide miRNA genes as 
described by Fromm et al [23]. Briefly, a consistent set of criteria for annotation of miRNAs is used 
that includes (1) proven genomic origin of (2) expressed hairpin precursor that (3) show at least 16 nt 
complementarity of both strands; (4) expression of 20-26 nt long reads with (5) highly conserved 
start positions (5’ homogeneity); (6) reads originate from both arms of the precursor and (7) show a 
2 nt offset created by the two sequential RNAse III cuts (Drosha/Dicer). Probes that clearly violated at 
least one of the criteria were omitted from proposed signatures, as were miRNAs no longer listed in 
miRBASE. miRNA target search is explained in Additional file 1B.  
Reproducible research 
In an effort to make our results reproducible [24], most of the scripts used in this work are accessible 
through a github repository at https://github.com/ous-uio-bioinfo-core/Eurocan_microRNA. Lists of 
all miRNAs differentially expressed are available in the additional material with explanation given in 
Additional file 1C2. The repository contains r-scripts, r-markdown, QC-plots and additional 
descriptions, but not the data which is accessible from https://www.ebi.ac.uk/arrayexpress accession 
number E-MTAB-3759 (AHUS dataset) [Accesson granted reviewer with Username: Reviewer_E-
MTAB-3759 and Password: hjynmtmx] and https://www.ebi.ac.uk/ega/ accession number 
EGAS00000000122 (METABRIC dataset, approval needed). Validation was performed using an 
external dataset, Volinia et al [1]. 
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Results and discussion 
Lack of replicability is a major challenge of gene expression profiling studies. To improve robustness 
of our signatures, two separate cohorts were used where only miRNAs significant in two separate 
statistical approaches were included. Validation was performed using results from a third, external 
dataset was performed. Stratification by subtypes helps identify robust signatures by reducing 
heterogeneity.  
Transition from normal breast tissue to DCIS 
A total of 70 miRNAs were identified as differentially expressed between normal breast tissue and 
DCIS in both datasets and with both analytical approaches (meta-analysis and merged approach) 
(Additional file 3). Of these, 53 were analysed by Volinia et al [1] and 27 were found differentially 
expressed in the same direction in their study and are proposed as a DCIS signature (Table 12 and 
Figure 1). miRNA-210-3p was significantly up-regulated in both our analyses (Additional file 3), but 
was down-regulated in the same transition in Volinia et al and is hence excluded from our proposed 
signature.  
We found that the major alterations in miRNAs expression occur early in breast carcinogenesis and 
are detected in the transition from normal breast tissue to DCIS, as previous studies have shown 
[1,2]. In a previous analysis published by Tahiri et al, we studied the deregulation of miRNA 
expression in normal-benign-malignant specimens [2]. Of the 53 miRNAs analysed in the transition 
from normal to DCIS by this study and Volinia et al, 24 were also found deregulated in benign 
tumours (Additional file 1D 4 and 5). Of the 27 validated miRNAs differentially expressed between 
normal and DCIS, 14 are also found as differentially expressed in benign tumours in the same 
direction (Additional file 1D4). These include miR-21, let-7 and the miR-200 family. These results 
suggest that miRNA deregulation appears very early in proliferation progression and cannot be easily 
separated from markers of malignancy. Despite a limited number of DCIS samples, 70 miRNAs were 
identified as significantly altered using both statistical approaches (Additional file 3). Contrasting 
small numbers of DCIS and normal samples inherently makes all statistical approaches used to 
measure miRNA levels and the different bioinformatic processing of the raw data bias-prone. 
Nevertheless, the proposed signature of 27 miRNAs robustly emerges in all three independent 
cohorts, including an external dataset [1]. These miRNAs are proposed as a transition signature from 
normal breast tissue to DCIS (Table 12). Hierarchical clustering of all normal and DCIS samples in each 
dataset based on these 27 miRNAs is illustrated in Figure 2, while clustering on the 256 expressed 
miRNAs is shown in Additional file 1E.  
Some of the miRNAs have previously been found similarly altered. miR-21 is one of the most studied 
cancer-related miRNAs and several studies have found miR-21 up-regulated in DCIS samples 
compared with non-malignant breast tissue [25]. The expression of this miRNA was found at elevated 
levels with increasing stages of breast cancer, and a corresponding increase could be measured in the 
serum [26], suggesting it as a likely serum biomarker. This was also the miRNA with the highest fold 
change in our study.  miR-21 is induced by inflammatory stimuli and is involved in the regulation of 
inflammation. Particularly, miR-21 acts as a mediator of the anti-inflammatory response in 
macrophages, but it has also been found to promote inflammatory mediators in carcinogenesis [27]. 
An increased expression of miR-21 in DCIS may thus reflect both a carcinogenic drive and the 
inflammatory host response to malignant alterations. The MIR21 gene is located at 17q23.2, in a 
region that harbours several oncogenes and that has been found amplified in breast carcinomas [28]. 
Residing close to known oncogenes, its expression levels will be a compoundmay be both a driver 
and passenger effect. The expression of this miRNA correlates positively with copy number 
alterations and negatively with methylation [9].  
All five members of the miRNA-200 family (residing on two different chromosomes) are up-regulated 
in DCIS compared to normal breast tissue in our data; (miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-
141-3p and miR-429). Three of the miRNAs are validated in Volinia et al (miR-200b-3p, miR-200c-3p 
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and miR-429). These miRNAs are enriched in epithelial tissues [29] and are induced by TP53 [30]. The 
tumour suppressive function of these miRNAs is demonstrated by high expression inhibiting the 
epithelial to mesenchymal transition through repressed transcription of ZEB1 and ZEB2, two E-
cadherin transcriptional repressors [30]. At the same time, miR-200-expression has been associated 
with increased risk of metastasis in breast cancer and in mouse models [31]. An up-regulation of 
these miRNAs in the DCIS samples could indicate repression of epithelial mesenchymal transition and 
increase in E-cadherin transcription which is in line with the non-invasive nature of this disease. A 
relative increase in the epithelial compartment of the DCIS samples cannot be excluded. We do not 
find members of the miR-200 family up-regulated in any of the subtypes of invasive primary tumours, 
and have no data from metastases.  
DCIS is heterogeneous, and molecular subtypes have been defined [32]. Due to a limited sample size, 
stratification by subtypes was not possible in our analyses and lack of stratification may increase 
noise so that we lose some information about the biology involved in the early stages of the 
carcinogenic process.  
Target search of the 27 miRNAs was performed separately for miRNAs up- and down-regulated in the 
transition to DCIS as described in Additional file 1B. For miRNAs up-regulated in DCIS, 5616 predicted 
and validated targets were identified. Of these, 284 were cancer-related. For miRNAs down-
regulated in DCIS, 7178 predicted and validated targets were identified, of which 272 were cancer-
associated. Complete lists are given in Additional file 4.  
Transition from DCIS to invasive breast cancer  
No miRNAs were consistently identified as differentially expressed when DCIS and invasive samples 
per se were compared in both analytical approaches. Volinia et al have published an invasiveness 
signature of miRNAs altered in the transition from DCIS to invasive carcinoma [1]. Of their nine 
miRNAs, only one was borderline significant in our analysis: Let-7d with an FDR 0.06 and a log fold 
change of 0.65 (Additional file 56).  
The inconsistency of miRNA signatures in the transition from DCIS to invasive carcinoma may partly 
be due to low statistical power as the number of DCIS samples is low but it is, in our view, also due to 
the heterogeneity of breast cancer.  
Overall, we show a higher rate of inter-study concordance in differentially-expressed miRNAs 
observed for normal-to-DCIS transition compared to DCIS-to-carcinoma transition. This may reflect 
the more fundamental changes taking place at the initiation of tumourigenesis, statistically 
reinforced by the relative uniformity of the normal samples compared to carcinomas. Thus, a 
subtype-stratified approach for carcinomas is better suited to identify biological processesd in early 
DCIS-to-carcinoma transitions. Still, a subtype-stratified approach may give more representative 
information about the biological processes in the early transitional stages as well (from normal tissue 
to DCIS).  
Subtype-specific signatures of invasive breast carcinomas 
We have identified subtype-specific signatures of invasive breast carcinomas (Tables 32 and 43, 
Figure 1). Fold change and FDR-values of the miRNAs differentially expressed from DCIS to each 
subtype are listed in Additional files 67-245. Subtype stratification based on molecular signatures 
(PAM50 or IC) results in more significant miRNAs than stratification based on ER, PgR and HER2 
alone, indicating a better representation of the intrinsic biology of the samples. For IHC-based 
subtypes (Additional files 221-254), no miRNAs were differentially expressed between DCIS and the 
ER+ subtypes. Six miRNAs were down-regulated in ER-/HER2+ invasive samples compared with DCIS 
of which five belong to the miR-30-family (miR-30a-5p, miR-30a-3p, miR-30c-2-3p, miR-30c-5p-miR-
30e-3p, miR-139-5p and miR-221-3p). miR-139-5p was down-regulated in both ER- subtypes, while 
miR-887-3p was down-regulated in triple negative breast cancer only.  
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Ten miRNAs were deregulated in several subtypes. These may serve as more general markers, but 
they were not identified without stratification by the invasive subtypes. miR-125b2-3p, miR-139-5p, 
miR-140-3p, miR-378a-3p, miR-221-3p, miR-31p and miR-433-3p were all down-regulated in the 
invasive subtypes and have been reported as tumour suppressors in the literature [33-36]. Three 
miRNAs (miR-505, miR-29c-5p and miR-30a-3p) have a conflicting direction of regulation in the 
transition from DCIS to invasive subtypes. The two latter are up-regulation in the transition from DCIS 
to luminal subtypes, but down-regulated in the more aggressive HER2 subtype. 
One miRNA, miR-139-5p, was down-regulated in the poor prognosis subtypes; HER2-enriched, 
luminal B, basal-like and in the HER2-enriched IC5 tumours as well as in triple negative tumours, but 
not in the good prognosis subtypes, luminal A and IC3 (in the latter, no miRNAs are significantly 
deregulated). This miRNA is a well known tumour suppressor and is a putative biomarker for several 
cancer types  and has been found to bedown-regulated in triple negative breast carcinomas and with 
increasing involvement of lymph nodes [34].  
Down-regulation of several members of the miR-30 family was observed in HER2-associated tumours 
(Tables 32 and Additional file 243). Expression of miRNAs in this family has been reported to confer 
favourable prognosis [37]. miR-30a-3p was up-regulated in luminal A tumours and in IC8 which is 
dominated by luminal A samples. In the literature, this miRNA is described as a tumour suppressor 
and low expression has been associated with early recurrence [38]. Expression of miR-30c-2-3p, 
which was down-regulated in HER2-enriched and HER2-positive tumours in our data, has previously 
been found up-regulated in luminal A tumours and down-regulated in basal-like and HER2-enriched 
tumours [37]. This miRNA is an independent positive prognostic factor and has been found to reduce 
resistance to doxorubicin and paclitaxel [37] and to regulate breast cancer cell invasion [39].  A low 
expression in the poor prognosis HER2-enriched subtype is in line with studies that have shown that 
high expression of HER2 is associated with risk of progression [40]. Both miR-30a-3p and 30c-2-3p are 
down-regulated in the transition from DCIS to IC5 which is dominated by the HER2 subtype (p<0.02), 
but the significance does not hold after correction for multiple testing. miR-31-5p was also down-
regulated in several subtypes (luminal B, IC1, IC2 and IC8) and is also known to be a tumour 
suppressor [41].  
miR-29c-5p was up-regulated in luminal A and B tumours and down-regulated in basal-like tumours, 
suggesting that it might be a marker of luminal invasiveness. The same miRNA is up-regulated from 
DCIS to IC1, 2, 6, 7 and 8 which are all dominated by luminal samples, but down-regulated in the 
transition to IC10 which is dominated by basal-like samples. Dvinge and colleagues found the miR- 29 
family involved in the modulatory network of IC4 related to inflammatory response, but it was not 
significantly regulated in the transition from DCIS to IC4. Our findings correspond well with previous 
findings that miR-29c suppress cell migration and invasion (in colorectal cancer)[42] and that high 
expression of miR-29c is associated with favourable prognosis [43].  
Chromosomal location 
An overview of miRNA expression related to chromosomal location is presented in Figure 23. Down-
regulation of miRNA transcripts of genes located on chromosome 14 is dominating. Chromosomal 
location for deregulated miRNAs was determined and cytobands with more than one deregulated 
miRNA during breast cancer progression were identified (Additional file 1F26). Two miRNA-clusters 
located on 14q32 were deregulated in the transition from DCIS to various invasive subtypes, 
primarily luminal B and IC10 (good outcome basal-like samples). One miRNA was up-regulated (miR-
342-3p) whereas the others were all down-regulated. 14q32 is a very well studied imprinted genomic 
region, where the miRNA clusters are often internally co-regulated and have been found down-
regulated in many cancers, including breast cancer [9]. Deletions in this region have been associated 
with BRCA2-mutations [42]which in turn often share a similar phenotype with luminal B tumours [43] 
which matches our results well. Loss in 14q32.33 has been associated with poor prognosis [44], 
which is another feature of luminal B and IC10 tumours. There are however many miRNAs located in 
10 
 
10 
 
14q32 and of the 31 miRNAs from this region expressed in our data, the majority (n=17) of the 
expressed miRNAs (n=31) were not significantly altered.  
Generally, there is a down-regulation of deregulated miRNAs during progression, but chromosome 
1q (particularly 1q32.2) has overrepresentation of up-regulated miRNAs (Figure 32). This 
chromosomal region is amplified in many breast carcinomas, both of indolent and aggressive 
subtypes [44]. Chromosome 14 (particularly 14q32.2) is characterized by a large proportion of down-
regulated miRNAs.  
Four miRNAs with genes located at 5q32 were down-regulated in the transition from normal breast 
tissue to DCIS (Table 21); miR-143-5p, miR-145-3p, miR-145-5p and miR-378a-3p, the latter being 
down-regulated in several invasive sub-types as well (luminal A, luminal B, IC2, IC6 and IC8) 
(Additional file 1F).. miR-143 and miR-145 have been suggested to have tumour suppressor function 
[46] and have been found down-regulated in triple negative breast cancer [47]. Chivukala and 
colleagues found that these miRNAs are not expressed in non-malignant colonic epithelial cells and 
the apparent down-regulation in tumours may be due to a smaller fraction of stromal cells 
expressing these miRNAs [48,49].  This is in line with our findings that all breast tumour subtypes 
have low expression of these miRNAs compared with non-malignant tissue which usually contains 
more stromal cells.  
Step-wise progression from normal to DCIS to invasive cancer 
Fourteen of the 27 miRNAs validated in the transition from normal breast tissue to DCIS, were also 
found significantly altered in the progression from DCIS to a specific breast cancer subtype. Of these, 
seven were consistently down-regulated (let-7c-5p, miR-125b-5p, miR-140-3p, miR-145-3p, miR-145-
5p, miR-193a-5p and miR-378a-3p) consistent with a subtype-specific tumour suppressive function . 
Four miRNA were consistently up-regulated, indicating an oncogenic potential (miR-106b-5p, miR-
142, miR-342-3p, miR-425-5p).  
One miRNA was down-regulated in the transition to DCIS, but had conflicting deregulation in the 
invasive transition (miR-99a-5p was down-regulated in luminal B and up-regulated in normal-like).  
Two miRNAs were down-regulated in DCIS and up-regulated in invasive subtypes (luminal B and IC1 
tumours for miR-193b-3p and normal-like for miR-497-5p).. The stepwise eExpression of these 
miRNAs is illustrated in Additional file 2527).  
miR-210 has previously been identified as a marker of poor prognosis in breast cancer and other 
carcinomas [1]. Volinia et al found miR-210 to be down-regulated in DCIS compared with normal 
breast tissue, but up-regulated in invasive carcinomas compared with DCIS [1]. In our data, miR-210 
was up-regulated in DCIS compared with normal tissue and was not detected as significantly altered 
in any invasive subtype. The role of this miRNA in breast carcinogenesis is still unclear.   
Possible clinical application 
These miRNA signatures provide candidates for miRNA serum markers of breast carcinogenesis. Most 
of the miRNAs identified are detectable in serum (unpublished data from our lab). Testing these 
miRNAs in serum and their association with breast cancer disease may enable diagnostic tests that 
may add information to mammography/ultrasound in the diagnosis/follow- up of women with high 
risk of developing breast malignancy.  
The main purpose of identifying miRNA signatures of progression is the study of the carcinogenic 
process at a molecular level. However, miRNAs associated with breast cancer progression may also 
serve as markers of the disease in surgically removed tissue and possibly even in the serum. There is 
reason to believe that miRNAs are selectively secreted into circulation and many miRNAs present in 
the tissue will not be present at significant levels in the serum. Separate studies are therefore 
needed in plasma/serum to explore these possibilities. Of the 12 miRNAs in our DCIS signature that 
was up-regulated in DCIS, 6 are identified at a significant level (median of all samples had a higher 
than minimum abundance in serum): miR-21-5p, miR-106b-5p, 142-3p, miR-342-3p, miR-425-5p, let-
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7b-5p). Of the remaining up-regulated miRNAs, the literature supports a possible serum biomarker 
role for miR-155 [45] and miR-200c [46].    
 
Replicability of miRNA signatures 
Several studies have shown limited overlap of differentially expressed miRNAs from microarrays and 
sequencing [47]. Although sequencing of miRNAs is becoming more of a gold standard for measuring 
the expression levels of miRNAs, there are challenges to both library preparation and data analysis. 
The most varying miRNAs should, however, be identified by both methods. The Agilent microarray 
platform has been found to be of the best performers in identifying true differentially expressed 
miRNAs [47].  
Dvinge and colleagues studied miRNA-expression in the large METABRIC dataset, which was also 
included in this study. They found that individual miRNAs are not robust prognostic markers [11].  
They also found that miRNA signatures were not highly correlated with clinical or histopathological 
traits, but to a larger extent with molecular traits such as PAM50 and IC-subtype. This corresponds 
with our finding that miRNA signatures were identified in the transition to PAM50 subtypes, but not 
to immunohistologically defined subtypes.  
Using two different statistical approaches, we aimed at removing statistically obtained false positive 
miRNAs. The number of miRNAs significant in each approach is given in Additional files 3 and 56-245. 
Generally, the merged approach identified more miRNAs than the meta-analysis, while most of the 
miRNAs identified in the meta-analysis were also present in the merged approach.  
 
Conclusions 
We propose miRNA signatures characterizing the transition from normal breast to DCIS and the 
invasive transformation from DCIS to several PAM50 and IC subtype of breast cancer. These 
signatures are candidate biomarkers of breast carcinogenesis (DCIS and invasive subtypes of breast 
cancer) and their clinical value deserves to be tested in prospective setting. Most of the miRNAs are 
detectable in the serum and could possibly add clinical value to mammography in a diagnostic 
setting. We have also demonstrated that the heterogeneous nature of breast cancer necessitates 
stratification by subtype for identification of robust signatures and that stratification by PAM50 or IC 
subtype gives more significant miRNAs than stratification based on IHC scores.  
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Figure legends and tables 
Figure 1. Summary of differentially expressed miRNAs. miRNAs differentially expressed between 
normal breast tissue and DCIS are validated in an external dataset. miRNAs differentially expressed 
between DCIS and the PAM50 and IC subtypes of invasive breast cancer are proposed as signatures 
of invasive breast carcinomas. All significant miRNAs are displayed for most subtypes, but selected 
miRNAs are displayed for the transition from normal to DCIS and from DCIS to subtypes luminal B, 
IC1, IC8 and IC10 due to large number of significant miRNAs (n>15). See Tables 12, 32, and 43 for 
complete lists. Bold miRNAs are consistently differentially expressed from normal breast tissue to 
DCIS and from DCIS to an invasive subtype. Red = up-regulated. Blue = down-regulated.  
Figure 2. Hierarchical clustering of normal and DCIS samples based on the proposed DCIS miRNA 
signature. The clustering was performed for the two datasets AHUS and METABRIC separately.   
Figure 23. Overview of genomic localisation of miRNAs deregulated during breast cancer 
progression. Alterations from normal tissue to DCIS and from DCIS to PAM50 and IC subtypes are 
shown. No miRNAs are deregulated from DCIS to IC3 or IC4. Red = up-regulated. Blue = down-
regulated. 
 
